Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ($48.43).

How significant is this acquisition relative to the CEO's existing position? The purchase of ~208,000 shares represents a 13% expansion of Michael F. Mahoney's total equity interest. Following the transaction, he maintains a combined position of ~1.6 million shares valued at approximately $78.08 million based on the Aug. 3, 2026 market close.

What was the execution context for this $9.0 million trade? The acquisition was completed through multiple trades at prices ranging from $47.87 to $48.47 per share. According to filing footnotes, most of the transaction was a direct purchase by the executive, with about 22,000 shares bought as a discretionary rebalancing of holdings within the company's 401(k) Retirement Savings Plan.

How does this purchase align with recent stock performance? The transaction was executed following a period of negative price momentum, as Boston Scientific recorded a -54% return over the 12 months ending on the transaction date. As of the Aug. 4, 2026 market close, the stock was priced at $49.09, slightly above the CEO's weighted-average entry price of $48.34.

What is the current structure of the CEO's beneficial ownership? The majority of the CEO's holdings are held directly, totaling 1,590,024 shares. In addition to the 22,119 shares held indirectly through a 401(k) plan, Michael F. Mahoney also holds derivative securities in the form of stock options and awards.

Boston Scientific designs, manufactures, and commercializes a comprehensive portfolio of innovative medical devices across three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular, serving diverse interventional medical specialties globally.

The company generates revenue through the development and sale of specialized medical devices and solutions that address clinical needs across gastrointestinal, cardiovascular, neuromodulation, and surgical intervention markets.